Research program Live corpus

Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.

PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,316 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

Explore Platform → See latest papers

40,316 Papers indexed

1,440 Papers AI scored

40,316 Ranked papers

100.0% Coverage

Featured discovery ● Live

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

AI Score 79.80 Active signal

Grade A

Final score 88.16

Narrative velocity Not calculated

Confidence Building

CHIP-AML22 is a multinational pediatric de novo AML trial protocol integrating risk-adapted therapy, randomized gemtuzumab ozogamicin and consolidation-course comparisons, subgroup-specific quizartinib, and toxicity-reduction measures.

Read full analysis →

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE

↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing

TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Published Jun 20, 2026

Journal Trials

88.16 Ranking score

A grade PMID 42321916

View analysis →

Bicistronic CD19/CD22 CAR T-Cell Therapy in Pediatric B-Cell Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial.

Published Sep 03, 2026

Journal JAMA oncology

87.88 Ranking score

A grade PMID 42690647

View analysis →

Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled, phase 3 trial.

Published Jul 01, 2026

Journal The Lancet. Oncology

87.73 Ranking score

A grade PMID 42372741

View analysis →

Umbilical cord blood natural killer cells improve anti-GD2 antibody efficacy in neuroblastoma: from mouse to human.

Published May 30, 2026

Journal Oncoimmunology

87.38 Ranking score

A grade PMID 42216567

View analysis →

Medial retropharyngeal nodal region sparing radiotherapy in nasopharyngeal carcinoma: five year analysis of open label, non-inferiority, multicentre, randomised phase 3 trial.

Published Mar 31, 2026

Journal BMJ (Clinical research ed.)

87.15 Ranking score

A grade PMID 41916649

View analysis →

Therapy and biomarker dependent progression-free survival in infant sonic hedgehog medulloblastoma: a multi-national retrospective cohort study.

Published May 18, 2026

Journal EClinicalMedicine

86.97 Ranking score

A grade PMID 42382416

View analysis →

Integrated biomarker and treatment correlates of prognosis in infant non-WNT/non-SHH medulloblastoma: a multinational retrospective cohort study.

Published May 18, 2026

Journal The Lancet. Child & adolescent health

85.99 Ranking score

A grade PMID 42150584

View analysis →

Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia.

Published Sep 17, 2026

Journal The New England journal of medicine

85.54 Ranking score

B grade PMID 42748428

View analysis →

Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma.

Published Feb 20, 2026

Journal bioRxiv : the preprint server for biology

85.22 Ranking score

A grade PMID 41756844

View analysis →

A Phase I/II Trial of Anti-CD22/CD19 CAR-T Cell Therapy, CART2219.1, in Adult and Pediatric Relapsed/Refractory B-ALL.

Published Sep 21, 2026

Journal Blood cancer discovery

85.08 Ranking score

A grade PMID 42765973

View analysis →

T-cell receptor-engineered T-cell therapy using a glypican-3-specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2-positive glypican-3-expressing cancers.

Published Jun 26, 2026

Journal Cancer letters

85.07 Ranking score

A grade PMID 42362103

View analysis →

Gilteritinib and chemotherapy in children with relapsed/refractory FLT3-ITD AML: results from the phase 1/2 SKIPPER trial.

Published Jul 14, 2026

Journal Blood advances

84.86 Ranking score

A grade PMID 42101908

View analysis →

LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-11 10:15 AM

1 Sensitive LC-MS/MS Method for Simultaneous Quantification of Alectinib and Its Major Metabolite M4 in Limited-Volume Human Plasma. Biomedical chromatography : BMC — Nov 11, 2026 2 Patient reimbursement in therapeutic cancer clinical trials: An 18-year multicenter experience. Cancer — Nov 11, 2026 3 Adulthood risk of non-communicable diseases associated with childhood and adolescent malnutrition in low- and middle-income countries: a systematic review of observational studies. BMJ global health — Nov 11, 2026 4 Parental night shift work and risk of breast cancer in daughters. Environmental research — Nov 11, 2026 5 Influence of diaphragm structure and function on the exercise ventilatory response in childhood cancer survivors and non-cancer controls. Respiratory medicine — Nov 11, 2026 6 Pregnancy and classic Hodgkin lymphoma: real world outcomes from a single center in Egypt. Current problems in cancer — Nov 11, 2026 7 Racial and Ethnic Differences in the Incidence of Langerhans Cell Histiocytosis Across the Age Spectrum. Blood advances — Nov 11, 2026 8 International Cross-Age Consensus Guideline on Measurable Residual Disease Assessment in Acute Lymphoblastic Leukemia. Blood — Nov 11, 2026

WHAT THE AI SEES TODAY

Live pediatric oncology intelligence

● Live

↗

Therapeutic signal strength is updating across newly scored pediatric oncology literature.

✦

Mechanism clusters are forming around tumor biology, immune response, targeted therapy, treatment resistance, and drug repurposing.

⌁

Daily literature intake feeds the ranking engine and refreshes study-design, human-relevance, and therapeutic-relevance scores.

●

40,316 pediatric cancer records are currently visible under this search.

PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40316 results

[MEP-44] Abdominal Aortic Coarctation in an Adolescent Patient.

PMID 40322141 Published: 2024-12-31 Ingested: 2026-08-02 12:02 AM Turk gogus kalp damar cerrahisi dergisi

AI -

Standard 46.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 46.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

A Rare Intersection: Wilms Tumor in a Patient with PIGO Syndrome.

PMID 40320634 Published: 2025-05-04 Ingested: 2026-08-02 12:04 AM Pediatric blood & cancer

AI -

Standard 46.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 46.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Net-like Superficial Vascular Malformation in a 5-Year-Old Girl: A Case Report With Clinicopathological Correlation and a Comprehensive Literature Review.

PMID 40314645 Published: 2025-04-22 Ingested: 2026-08-02 12:04 AM The American Journal of dermatopathology

AI -

Standard 46.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 46.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

CEBPA-associated familial acute myeloid leukemia mimicking Werner syndrome: a case report.

PMID 40313597 Published: 2025-04-17 Ingested: 2026-08-02 12:03 AM Frontiers in genetics

AI -

Standard 46.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 46.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

Eligibility for Cochlear Implant Candidacy Evaluation in Childhood Cancer Survivors.

PMID 40310640 Published: 2025-07-01 Ingested: 2026-08-02 12:04 AM JAMA oncology

AI -

Standard 46.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 46.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Case Report: Agranulocytosis in a Child Following Metamizole Use - A Diagnostic Challenge.

PMID 40302291 Published: 2025-04-01 Ingested: 2026-08-02 12:04 AM Acta medica academica

AI -

Standard 46.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 46.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

Two-fold increased risk of melanoma in childhood cancer survivors.

PMID 40298162 Published: 2025-05-01 Ingested: 2026-08-02 12:04 AM Cancer

AI -

Standard 46.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 46.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Location and extent of disease predicts outcome of neurofibromatosis type 1-related pediatric low-grade gliomas.

PMID 40296988 Published: 2025-02-28 Ingested: 2026-08-02 12:03 AM Neuro-oncology advances

AI -

Standard 46.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 46.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Rethinking neurocognitive outcomes in adult survivors of childhood medulloblastoma: Progress and unmet challenges.

PMID 40296361 Published: 2025-07-30 Ingested: 2026-08-02 12:12 AM Neuro-oncology

AI -

Standard 46.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 46.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Intravascular lobular capillary hemangioma of the temporal artery arising in an older adult: a case report.

PMID 40290850 Published: 2025-04-15 Ingested: 2026-08-02 12:04 AM American journal of ophthalmology case reports

AI -

Standard 46.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 46.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

Extranasopharyngeal Angiofibroma in the Tongue: A Case Report With Literature Review.

PMID 40285340 Published: 2025-04-25 Ingested: 2026-08-02 12:04 AM Ear, nose, & throat journal

AI -

Standard 46.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 46.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial.

PMID 40281208 Published: 2025-04-25 Ingested: 2026-08-02 12:04 AM Bone marrow transplantation

AI -

Standard 46.5

Final -

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 46.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 10.0; sample size: 20.0; recency: 90.0; abstract quality: 0.0.

Page 3100 of 3360

Open the Research
Intelligence Map

Finding therapies hidden in 40,316 pediatric cancer papers.

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Ranked Discovery Journal Articles

Database feed

All ranked pediatric cancer papers

AI-assisted research information

Open the Research Intelligence Map